OBJECTIVE: To evaluate the effect of age adjustment on baseline erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in patients with late-onset rheumatoid arthritis (LORA, age > or = 55 yrs) and younger-onset RA (YORA, age < 55 yrs) in a cohort with early, rheumatoid factor (RF) positive RA that has not received disease modifying antirheumatic drugs (DMARD). METHODS: In an ongoing prospective cohort study of 263 patients with seropositive RA who were enrolled within 14 months of symptom onset, baseline assessments included ESR, CRP, tender and swollen joint counts, and functional status. Westergren ESR determinations were performed in the rheumatologist's office or in a local laboratory using appropriate methods. CRP were performed at the Specialty Laboratories in Santa Monica, CA, using Behring nephelometry. Percentages of patients with greater than the upper limit of normal (ULN) laboratory values using both age-unadjusted and age-adjusted ESR and CRP values were determined. The late-onset and younger-onset RA patients were compared using Wilcoxon rank-sum and chi-square tests. RESULTS: At study entry, both the YORA and LORA patients had comparable symptom duration, disease activity scores, tender and swollen joint counts, and Health Assessment Questionnaire values. RF, CRP, and ESR were significantly higher (p < 0.05) in LORA patients. Although the percentages of patients with age-unadjusted ESR and CRP above ULN were higher in LORA patients, the percentages exceeding the age-adjusted ULN did not differ significantly between the YORA and LORA groups. CONCLUSION: In patients with late-onset and younger-onset RA with similar disease duration and severity, the apparent discrepancy in elevation of both the baseline ESR and CRP disappears after age-adjustment.
OBJECTIVE: To evaluate the effect of age adjustment on baseline erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in patients with late-onset rheumatoid arthritis (LORA, age > or = 55 yrs) and younger-onset RA (YORA, age < 55 yrs) in a cohort with early, rheumatoid factor (RF) positive RA that has not received disease modifying antirheumatic drugs (DMARD). METHODS: In an ongoing prospective cohort study of 263 patients with seropositive RA who were enrolled within 14 months of symptom onset, baseline assessments included ESR, CRP, tender and swollen joint counts, and functional status. Westergren ESR determinations were performed in the rheumatologist's office or in a local laboratory using appropriate methods. CRP were performed at the Specialty Laboratories in Santa Monica, CA, using Behring nephelometry. Percentages of patients with greater than the upper limit of normal (ULN) laboratory values using both age-unadjusted and age-adjusted ESR and CRP values were determined. The late-onset and younger-onset RApatients were compared using Wilcoxon rank-sum and chi-square tests. RESULTS: At study entry, both the YORA and LORA patients had comparable symptom duration, disease activity scores, tender and swollen joint counts, and Health Assessment Questionnaire values. RF, CRP, and ESR were significantly higher (p < 0.05) in LORA patients. Although the percentages of patients with age-unadjusted ESR and CRP above ULN were higher in LORA patients, the percentages exceeding the age-adjusted ULN did not differ significantly between the YORA and LORA groups. CONCLUSION: In patients with late-onset and younger-onset RA with similar disease duration and severity, the apparent discrepancy in elevation of both the baseline ESR and CRP disappears after age-adjustment.
Authors: Ashutosh Tamhane; David T Redden; Gerald McGwin; Elizabeth E Brown; Andrew O Westfall; Richard J Reynolds; Laura B Hughes; Doyt L Conn; Leigh F Callahan; Beth L Jonas; Edwin A Smith; Richard D Brasington; Larry W Moreland; S Louis Bridges Journal: J Rheumatol Date: 2013-08-15 Impact factor: 4.666
Authors: Veena K Ranganath; Erin L Duffy; Vikram K Garg; Thasia Woodworth; Mihaela Taylor; Harold E Paulus; Roy D Altman; David A Elashoff Journal: J Clin Rheumatol Date: 2019-04 Impact factor: 3.517
Authors: Veena K Ranganath; Jeonglim Yoon; Dinesh Khanna; Grace S Park; Daniel E Furst; David A Elashoff; Damini Jawaheer; John T Sharp; Richard H Gold; Edward C Keystone; Harold E Paulus Journal: Ann Rheum Dis Date: 2007-05-01 Impact factor: 19.103
Authors: William J Martin; Man Shim; Harold E Paulus; Sandeep Chaudhari; JingYuan Feng; David Elashoff; Theodore J Hahn; Veena K Ranganath Journal: J Clin Rheumatol Date: 2014-09 Impact factor: 3.517
Authors: John M Davis; Jaeyun Sung; Benjamin Hur; Vinod K Gupta; Harvey Huang; Kerry A Wright; Kenneth J Warrington; Veena Taneja Journal: Arthritis Res Ther Date: 2021-06-08 Impact factor: 5.156
Authors: Liseth Siemons; Peter M Ten Klooster; Harald E Vonkeman; Piet L C M van Riel; Cees A W Glas; Mart A F J van de Laar Journal: BMC Musculoskelet Disord Date: 2014-11-06 Impact factor: 2.362
Authors: Michelle J Ormseth; Cecilia P Chung; Annette M Oeser; Margery A Connelly; Tuulikki Sokka; Paolo Raggi; Joseph F Solus; James D Otvos; C Michael Stein Journal: Arthritis Res Ther Date: 2015-05-09 Impact factor: 5.156
Authors: Won Kyung Kim; Hwa-Jin Chung; Yuna Pyee; Tae Jun Choi; Hyen Joo Park; Ji-Young Hong; Joon-Shik Shin; Jin Ho Lee; In-Hyuk Ha; Sang Kook Lee Journal: Chin Med Date: 2016-04-11 Impact factor: 5.455